172 related articles for article (PubMed ID: 37537968)
1. A pilot trial of consolidation bevacizumab after hypo-fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non-squamous non-small-cell lung cancer.
Huo L; Chu C; Jiang X; Zheng S; Zhang P; Zhou R; Chen N; Guo J; Qiu B; Liu H
Cancer Med; 2023 Sep; 12(17):17638-17647. PubMed ID: 37537968
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
Zhou R; Qiu B; Xiong M; Liu Y; Peng K; Luo Y; Wang D; Liu F; Chen N; Guo J; Zhang J; Huang X; Rong Y; Liu H
Int J Radiat Oncol Biol Phys; 2023 Oct; 117(2):387-399. PubMed ID: 37100160
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
4. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Wozniak AJ; Moon J; Thomas CR; Kelly K; Mack PC; Gaspar LE; Raben D; Fitzgerald TJ; Pandya KJ; Gandara DR
Clin Lung Cancer; 2015 Sep; 16(5):340-7. PubMed ID: 25703100
[TBL] [Abstract][Full Text] [Related]
6. Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Merlotti A; Bruni A; Borghetti P; Ramella S; Scotti V; Trovò M; Chiari R; Lohr F; Ricardi U; Bria E; Pappagallo GL; D'Angelillo RM; Arcangeli S
Radiol Med; 2021 Aug; 126(8):1117-1128. PubMed ID: 33954898
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer.
Wu K; Zhu L; Wang J; Pan K; Wang B; Li X; Yang S; Xu X; Zhang M; Li X; Chen X; Ma S; Xia B
J Thorac Dis; 2019 Nov; 11(11):4529-4537. PubMed ID: 31903241
[TBL] [Abstract][Full Text] [Related]
10. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K
J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer.
Hasegawa T; Yanagitani N; Ohyanagi F; Kudo K; Horiike A; Tambo Y; Nishikawa S; Ariyasu R; Uchibori K; Kitazono S; Nishio M
Int J Clin Oncol; 2021 Mar; 26(3):507-514. PubMed ID: 33159605
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Seung SK; Ross HJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
15. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
[TBL] [Abstract][Full Text] [Related]
17. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
18. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
[TBL] [Abstract][Full Text] [Related]
19. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.
Wink KC; Belderbos JS; Dieleman EM; Rossi M; Rasch CR; Damhuis RA; Houben RM; Troost EG
Radiother Oncol; 2016 Mar; 118(3):453-9. PubMed ID: 26861738
[TBL] [Abstract][Full Text] [Related]
20. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]